Clinical trial · Interventional
Phase III Study of Gemcitabine Compared With UFT in Patients With Completely Resected Pathological Stage IB-IIIa Non Small Cell Lung Cancer
NCT00139971CI-TRIAL-00000260unknownPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To estimate the efficacy of Gemcitabine monotherapy compared to UFT as the post operative adjuvant chemotherapy for completely resected non-small cell lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| gemicitabine 1000mg/m2, day1 and day 8, every 3 week, 6 | Drug | — | UNRESOLVED |
| UFT 250mg/m2, daily for 1 year | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- 5 year survival rate
Secondary outcomes (1)
- measure
- Disease free survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. completely resected non small cell lung cancer 2. no prior anti cancer treatment for thoracic malignancy exept for this operation 3. pathological stage IB, II, and stage IIIA with only one station of n2 disease 4. PS 0-1 5. age 20-75 6. adequate organ function for chemotherapy 7. written informed consent Exclusion Criteria: 1. small cell lung cancer or low grade malignancy of lung cancer 2. incomplete resection 3. apparent interstitial pneumonitis at chest rentogenogram 4. inadequate condition for chemotherapy
References
Publications (0)
Data not yet available
No reference posted for this study.